Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Recruiting · NCT06841705 · Registry updated 2025-11-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, intestinal disorder | Recruiting | Phase 2 | 2025-11-04 | NCT06841705 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber/Brigham and Women's Cancer Center | 5 |
| Shilpa Grover, MD, MPH | 1 |
| Takeda | 163 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institute | Boston | United States | 133 |